Literature DB >> 8948296

Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score.

M L Prevoo1, A M van Gestel, M A van T Hof, M H van Rijswijk, L B van de Putte, P L van Riel.   

Abstract

In a prospective follow-up study of patients with early-onset rheumatoid arthritis, the prevalence of remission according to the 1981 American Rheumatism Association (ARA) preliminary criteria was evaluated. A total of 227 patients with a median follow-up of 3.9 yr and a total of 2832 follow-up visits were studied. The ARA remission criteria were fulfilled in 9.5% of these visits. The percentage of patients with at least one visit fulfilling the ARA criteria was for years 2-6 approximately 25%. Each year, approximately 15% of the patients were in remission for at least two consecutive visits. A comparison was made between the ARA remission criteria and the Disease Activity Score (DAS). DAS < 1.6 corresponded with being in remission according to the ARA criteria. The DAS is being proposed as a tool to define remission because absence of disease activity should be measured using the same method as for higher levels of disease activity, preferably on a continuous scale.

Entities:  

Mesh:

Year:  1996        PMID: 8948296     DOI: 10.1093/rheumatology/35.11.1101

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  95 in total

Review 1.  Clinical outcome measures in rheumatoid arthritis.

Authors:  P L van Riel; A M van Gestel
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

2.  Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands.

Authors:  C H van Jaarsveld; J W Jacobs; M J van der Veen; A A Blaauw; A A Kruize; D M Hofman; H L Brus; G A van Albada-Kuipers; A H Heurkens; E J ter Borg; H C Haanen; C van Booma-Frankfort; Y Schenk; J W Bijlsma
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

3.  Patients with rheumatoid arthritis in clinical care.

Authors:  J S Smolen; D Aletaha
Journal:  Ann Rheum Dis       Date:  2004-03       Impact factor: 19.103

4.  The relationship between disease activity and depressive symptoms severity and optimism--results from the IMPROVED study.

Authors:  L Heimans; K V C Wevers-de Boer; K Visser; H K Ronday; G M Steup-Beekman; M van Oosterhout; T W J Huizinga; E J Giltay; R C van der Mast; C F Allaart
Journal:  Clin Rheumatol       Date:  2013-07-24       Impact factor: 2.980

5.  Rheumatoid Arthritis: Early diagnosis and treatment outcomes.

Authors:  Behzad Heidari
Journal:  Caspian J Intern Med       Date:  2011

6.  MRI assessment of erosion repair in patients with long-standing rheumatoid arthritis receiving double-filtration plasmapheresis in addition to leflunomide and methotrexate: a randomized controlled trial.

Authors:  Xiaoxia Yu; Lei Zhang; Lixin Wang; Weiwei Lu; Fengyan Sun; Ping Xu; Guobin Lan
Journal:  Clin Rheumatol       Date:  2018-01-08       Impact factor: 2.980

7.  Improvement of large-joint ultrasonographic synovitis is delayed in patients with newly diagnosed rheumatoid arthritis: results of a 12-month clinical and ultrasonographic follow-up study of a local cohort.

Authors:  Halil Harman; İbrahim Tekeoğlu; Sibel Takçı; Ayhan Kamanlı; Kemal Nas; Sibel Harman
Journal:  Clin Rheumatol       Date:  2015-04-02       Impact factor: 2.980

8.  Great expectations of modern RA treatment.

Authors:  S Irvine; H C Capell
Journal:  Ann Rheum Dis       Date:  2005-09       Impact factor: 19.103

9.  [Austrian expert opinion on the standard for expert assessment of course of illness in patients with chronic polyarthritis (rheumatoid arthritis)].

Authors:  Klaus P Machold; Hans Peter Brezinsek; Burkhard F Leeb; Stephan Pflugbeil; Franz Rainer; Franz Singer; Martin Skoumal; Tanja A Stamm; Manfred Herold
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

10.  Leflunomide in active rheumatoid arthritis: a prospective study in daily practice.

Authors:  E N Van Roon; T L Th A Jansen; L Mourad; P M Houtman; G A W Bruyn; E N Griep; B Wilffert; H Tobi; J R B J Brouwers
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.